Physician profile
Adam Rock
NPI 1477907715
$3,870.80
in general payments reported to CMS, 2019-2025
32 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $325 · 2021: $106 · 2022: $213 · 2023: $521 · 2024: $347 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Food and Beverage: $1,065 · Education: $99.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Food and Beverage | $1,065.37 |
| Education | $99.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,500.00 | 2025 | |
| Novocure INC. | $230.50 | 2024-2025 | Optune Lua (Novottf-200t) |
| Galvanize Therapeutics, INC | $198.47 | 2023 | Aliya System |
| E.R. Squibb & Sons, L.L.C. | $155.60 | 2019-2021 | |
| Lilly USA, LLC | $141.82 | 2019 | |
| Seagen INC. | $125.76 | 2022 | |
| Celgene Corporation | $122.34 | 2020-2022 | |
| Janssen Biotech, INC. | $116.75 | 2025 | Rybrevant |
| Genzyme Corporation | $112.81 | 2019-2020 | |
| Aadi Bioscience, INC. | $105.20 | 2024 | Fyarro |
| Pfizer INC. | $104.22 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $99.19 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $97.88 | 2020-2024 | Keytruda |
| Amgen INC. | $97.48 | 2021-2025 | Lumakras, Imdelltra (Amg757) |
| Deciphera Pharmaceuticals INC. | $97.18 | 2024-2025 | Qinlock, Tgct |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $88.00 | 2019-2023 | Alunbrig |
| Alexion Pharmaceuticals, INC. | $77.00 | 2019 | |
| Exelixis INC. | $73.22 | 2019-2020 | |
| Mirati Therapeutics, INC. | $66.67 | 2023-2024 | Krazati |
| Incyte Corporation | $61.62 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $55.64 | 2019-2023 | Imfinzi |
| Pharmacyclics LLC, An Abbvie Company | $45.11 | 2019-2021 | |
| Stemline Therapeutics INC. | $38.01 | 2020 | |
| Daiichi Sankyo INC. | $30.67 | 2023 | |
| Eisai INC. | $20.86 | 2020 | |
| Musculoskeletal Transplant Foundation INC. | $8.80 | 2022 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Rock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.